

Alexandre Thibault Jacques Maria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2810836/publications.pdf>

Version: 2024-02-01

29
papers

1,138
citations

706676

14
h-index

511568

30
g-index

34
all docs

34
docs citations

34
times ranked

2049
citing authors

#	ARTICLE	IF	CITATIONS
1	Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e32-e32.	0.5	26
2	Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1356-1364.e2.	2.0	2
3	Aseptic Abscess Syndrome: Clinical Characteristics, Associated Diseases, and up to 30 Years' Evolution Data on a 71-Patient Series. <i>Journal of Clinical Medicine</i> , 2022, 11, 3669.	1.0	9
4	Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e10-e10.	0.5	114
5	Response to Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab by Avouac et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e38-e38.	0.5	14
6	Identification of a Novel Serum Proteomic Signature for Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 631539.	2.2	10
7	Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 143.	1.6	6
8	Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6837.	1.8	9
9	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	2.2	211
10	Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p. <i>Journal of Autoimmunity</i> , 2021, 121, 102660.	3.0	29
11	Lung Fibrosis Is Improved by Extracellular Vesicles from IFN γ -Primed Mesenchymal Stromal Cells in Murine Systemic Sclerosis. <i>Cells</i> , 2021, 10, 2727.	1.8	12
12	A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM-) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 2		
13	The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2315.	1.0	33
14	Flare of Antiphospholipid Syndrome in the Course of COVID-19. <i>TH Open</i> , 2020, 04, e207-e210.	0.7	13
15	Mastitis in Autoimmune Diseases: Review of the Literature, Diagnostic Pathway, and Pathophysiological Key Players. <i>Journal of Clinical Medicine</i> , 2020, 9, 958.	1.0	43
16	Biphasic Temporal Relationship between Cancers and Systemic Sclerosis: A Clinical Series from Montpellier University Hospital and Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 853.	1.0	15
17	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
18	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2571.	2.2	27
20	Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?. <i>Frontiers in Immunology</i> , 2018, 9, 2938.	2.2	48
21	iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 3056.	2.2	16
22	Impact of MPO-ANCA-mediated oxidative imbalance on renal vasculitis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1769-F1776.	1.3	6
23	Therapeutic innovation in adult-onset Still's disease (and other rare inflammatory disorders): how to secure evidence-based medicine?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1699-1701.	0.5	2
24	Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. <i>Frontiers in Immunology</i> , 2018, 9, 3112.	2.2	62
25	Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function. <i>Frontiers in Immunology</i> , 2017, 8, 988.	2.2	14
26	Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. <i>Journal of Autoimmunity</i> , 2016, 70, 31-39.	3.0	98
27	Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1013-1025.	2.9	70
28	Adult onset Still's disease (AOSD) in the era of biologic therapies: Dichotomous view for cytokine and clinical expressions. <i>Autoimmunity Reviews</i> , 2014, 13, 1149-1159.	2.5	140
29	Asymptomatic bilateral pulmonary embolism in Churg-Strauss syndrome. <i>European Respiratory Review</i> , 2012, 21, 75-77.	3.0	2